Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example백신 개발에 "생리학적 재정규화를 위한 시스템 치료" 접근 방식을 사용합니다. 코로나19를 예로 들어Article Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] 변종, [키워드] adaptive immune system approach current example induce infectious agent mimicry Mutation physiological Prevent Recombination replicate respiratory tract respiratory tracts sera Spread the disease therapeutic Vaccine Vaccine development variant virions virulent [DOI] 10.1080/21645515.2022.2043105 PMC 바로가기 [Article Type] Article
Using host receptor as a decoy to treat COVID-19: a solution for immune escape?Article Published on 2022-11-082022-11-16 Journal: EMBO Molecular Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 antibodies COVID-19 pandemic Critical dose driven by Efficacy evade host receptor immune Immunity IMPROVE inoculated K18-hACE2 transgenic mice Lung injury Medicine neutralizing antibody omicron pandemic reduce survival target the SARS-CoV-2 the vaccine therapeutic Therapies treat variant variants [DOI] 10.15252/emmm.202216818 PMC 바로가기
The effect of mutations on binding interactions between the SARS-CoV-2 receptor binding domain and neutralizing antibodies B38 and CB6Article Published on 2022-11-052022-11-15 Journal: Scientific Reports [Category] SARS, 변종, 진단, [키워드] antibodies antibody Antibody escape mutation binding binding interaction claimed COVID-19 human population IMPROVE molecular Mutation mutations N501Y Neutralizing antibodies neutralizing antibody pathogen Potential treatment predicted previous study Receptor binding domain responsible resulting S-RBD SARS-CoV-2 severity of COVID-19 the SARS-CoV-2 therapeutic [DOI] 10.1038/s41598-022-23482-5 PMC 바로가기
SARS-CoV-2 quasi-species analysis from patients with persistent nasopharyngeal sheddingArticle Published on 2022-11-042022-11-16 Journal: Scientific Reports [Category] SARS, 변종, [키워드] Analysis asked both groups clade Consequences Control COVID 19 deviation Evolution of SARS-CoV-2 genomic greater Human immune system immune evasion increase Infectious virus Interaction intra-individual investigated Mutation N501Y nasopharyngeal no significant difference P681H pandemic Patient patients performed persistence Prevent question RNA virus SARS-CoV-2 Sequencing Standard survival the SARS-CoV-2 therapeutic two group Variability variants viral propagation viral variant [DOI] 10.1038/s41598-022-22060-z PMC 바로가기
Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cellsArticle Published on 2022-11-022022-11-15 Journal: Scientific Reports [Category] SARS, 치료제, [키워드] Antiviral antivirals approved drug caused clinical evaluation Combination Compound concentrations conducted COVID-19 drug Effect Efficacy epithelial cell line exonuclease global pandemic HCV hepatitis C human lung human lung cell identify inhibitor moderate morbidity Mortality NS5A pharmacokinetic profiles Protein Remdesivir SARS Coronavirus SARS-CoV-2 SARS-CoV-2 replication Support synergy the SARS-CoV-2 therapeutic treatment strategy virus [DOI] 10.1038/s41598-022-21034-5 PMC 바로가기
Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crisesArticle Published on 2022-11-012022-11-16 Journal: Biophysical chemistry [Category] 신약개발, [키워드] affected analysis approach Cheminformatics clinical clinical study clinical trials complex compounds COVID-19 COVID-19 pandemic COVID-19 therapeutics deep learning develop Disease progression drug Drug repurposing drugs effort global healthcare Health help identify in silico Infectious disease information Intervention lack limitation machine machine learning miRNA MONITOR New pandemic pharmacological strategy Regulatory Research robust Side-effects System Systems biology systems biology. targets therapeutic therapeutic target Treatment strategies [DOI] 10.1016/j.bpc.2022.106891 PMC 바로가기
An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumabArticle Published on 2022-11-012022-11-15 Journal: Wiener medizinische Wochenschrift (1946) [Category] 바이오마커, 진단, [키워드] addition Autoimmunitiy brain tissue Central nervous system chronic inflammatory disease COVID-19 pandemic Demyelination disadvantage disease effective Evidence MRI Multiple multiple sclerosis neurodegeneration Neuroimmunology Patient primary mechanism Primary progressive multiple sclerosis provide Relapsing-remitting multiple sclerosis. Research T cell therapeutic Therapeutic approach Therapies therapy Treatment Trial [DOI] 10.1007/s10354-022-00939-w PMC 바로가기
Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case ReportArticle Published on 2022-11-012022-11-15 Journal: The American journal of case reports [Category] 진단, [키워드] anticoagulation Combination common contributing to Convalescent plasma therapy Course COVID-19 decrease Dexamethasone diagnosed discharge edema Factor healthy Hospitalized hypercoagulability initiated intravitreal injection knowledge occurred Oxygen therapy Patient Prophylactic pulmonary rebound Remdesivir report retinal vein retinal vein occlusion rivaroxaban Severe COVID-19 pneumonia significantly subsegmental the patient therapeutic therapy treated Treatment visual acuity was performed were excluded with COVID-19 [DOI] 10.12659/AJCR.937739 PMC 바로가기
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variantsArticle Published on 2022-11-012022-11-15 Journal: Cell Reports [Category] SARS, 변종, 진단, [키워드] Analysis antibodies antibody Beta breadth complementary conserved CP: Immunology CP: Microbiology Efficacy Hamster model human monoclonal antibodies immune Immune escape in vivo interact monoclonal antibody mutations neutralization neutralize Neutralizing activity omicron Omicron sublineages BA.1., BA.2, BA.2.12.1, and BA.4 overcome potent Protective provide raise reduced SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Spike protein Spread the receptor-binding domain the SARS-CoV-2 therapeutic therapeutic antibodies therapeutic efficacy Vaccine variant variants variants of concern variants of concern. [DOI] 10.1016/j.celrep.2022.111528 PMC 바로가기
Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathiesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 진단, [키워드] Administered administration age Alter analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibodies COVID-19 COVID-19 vaccination COVID-19 vaccine decrease dose enzyme-linked immunosorbent female healthy subjects IgA IgA titer IgG IgG titer IgM immune immunoassay Immunoglobulin impair indicate Interaction intravenous Intravenous immunoglobulin IVIG Microparticle mRNA vaccine observation Patient positive Prevalence reduce remained sera serological response serum serum titer significantly subsequent the antibody response therapeutic vaccination Vaccine vaccine dose vaccine interaction. [DOI] 10.1111/ene.15508 PMC 바로가기